Naloxone as mitochondrial phenotype rescuer in a 3D bioprinted LCHADD/VLCADD model
- 13D Bioprinting Core Facility, Departments of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria
Abstract
For patients diagnosed with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) or very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD), fasting episodes or high-energy demands remain life threatening. Due to the low incidence, clinical trials for novel LCHADD/VLCADD therapies are limited, and current mouse models recapitulate human symptoms only partially. Here, we report the use of mitochondrial morphology and 3D bioprinted, vascularized tissue models to establish a robust testing platform for dietary-based and experimental treatment approaches. Using this platform, we demonstrated that mitochondrial morphology is strictly regulated by NOX2-driven ROS formation. Treatment of LCHADD/VLCADD-derived fibroblasts with the NOX2-inhibitor naloxone led to the reassembly of mitochondrial structures controlled by DNM1L/MFN2. Using RNA transcriptomics, we identified a pro-fibrotic phenotype in LCHADD and VLCADD patient cells, which impaired vessel formation in fully 3D bioprinted human tissue equivalents. Metabolic supplementation with dietary approaches, which are used in standard therapy, partially improved vascularization. Naloxone induced the strongest improvement, restoring vessel length and network complexity to those of healthy controls, suggesting increased oxidative stress as main driver. Interestingly, naloxone had no effect on healthy fibroblasts, underscoring its safety. Taken together, these findings suggest the opioid antagonist naloxone as a potential rescue medication during LCHADD/VLCADD-driven metabolic crises.
Related
- Non-Destructive Quality Control Across the Life Cycle of Bioprinted Products
- Exploring clinically anchored therapeutic stratification and tumor-stroma heterogeneity using patient-derived 3D bioprinted primary liver cancer models.
- Sustained delivery of 3D-bioprinted stem cell-derived small extracellular vesicles promotes neural regeneration following traumatic brain injury via the CREB1/PGC-1α/FNDC5 axis.
- Directed combinatorial mutagenesis of Escherichia coli for complex phenotype engineering
- Muscular phenotype description of abnormal THOC2 splicing
BibTeX
@misc{degen2026naloxone,
title = {{Naloxone as mitochondrial phenotype rescuer in a 3D bioprinted LCHADD/VLCADD model}},
author = {A. Degen and M. Ausserlechner and V. Sturmlehner and C. Ploner and S. Tucci and D. Karall and H. Homaeirad and L. Neumann and J. Hagenbuchner},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.07.749837},
url = {https://www.biorxiv.org/content/10.64898/2026.09.07.749837v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Naloxone as mitochondrial phenotype rescuer in a 3D bioprinted LCHADD/VLCADD model
AU - A. Degen
AU - M. Ausserlechner
AU - V. Sturmlehner
AU - C. Ploner
AU - S. Tucci
AU - D. Karall
AU - H. Homaeirad
AU - L. Neumann
AU - J. Hagenbuchner
PY - 2026
DA - 2026/09/07
PB - bioRxiv
DO - 10.64898/2026.09.07.749837
UR - https://www.biorxiv.org/content/10.64898/2026.09.07.749837v1
AB - For patients diagnosed with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) or very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD), fasting episodes or high-energy demands remain life threatening. Due to the low incidence, clinical trials for novel LCHADD/VLCADD therapies are limited, and current mouse models recapitulate human symptoms only partially. Here, we report the use of mitochondrial morphology and 3D bioprinted, vascularized tissue models to establish a robust testing platform for dietary-based and experimental treatment approaches. Using this platform, we demonstrated that mitochondrial morphology is strictly regulated by NOX2-driven ROS formation. Treatment of LCHADD/VLCADD-derived fibroblasts with the NOX2-inhibitor naloxone led to the reassembly of mitochondrial structures controlled by DNM1L/MFN2. Using RNA transcriptomics, we identified a pro-fibrotic phenotype in LCHADD and VLCADD patient cells, which impaired vessel formation in fully 3D bioprinted human tissue equivalents. Metabolic supplementation with dietary approaches, which are used in standard therapy, partially improved vascularization. Naloxone induced the strongest improvement, restoring vessel length and network complexity to those of healthy controls, suggesting increased oxidative stress as main driver. Interestingly, naloxone had no effect on healthy fibroblasts, underscoring its safety. Taken together, these findings suggest the opioid antagonist naloxone as a potential rescue medication during LCHADD/VLCADD-driven metabolic crises.
ER -